Clinical applications of tissue engineering and cell therapy

The market for tissue engineering and cell therapy products is set to grow to nearly $32 billion by 2018. This figure includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical technologies. The largest segment in the overall market for regenerative medicine technologies and products comprises orthopedic applications. Other key sectors are cardiac and vascular disease, neurological diseases, diabetes, inflammatory diseases and dental decay and injury.

An overview (map) of the spectrum of clinical applications in tissue engineering and cell therapy is shown below:

Source: Report #S520

4 thoughts on “Clinical applications of tissue engineering and cell therapy”

  1. In principle, there is every reason to believe that most tissues can be regenerated with tissue engineering approaches. What governs the timing of any tissue engineering approach being realized is the size of the patient population, the clinical need (at least viewed by clinicians and third party payers) and the complexity of the tissue/organ structure and function. Conditions like empty nose syndrome may face a challenge in both the limited size of the patient population and the perceived clinical need.

  2. I know that I should probably know what you mean by “ENS”, but alas, I do not. (Perhaps this is because there is nothing in the context of this blog post referencing anything that could go by that acronym.) Help me out.